Title:
IL-15 MUTANT-FC/IL-15Rα SUBUNIT-FC HETERODIMER AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/037322
Kind Code:
A1
Abstract:
Disclosed in the present invention are an IL-15 mutant-Fc/IL-15Rα subunit-Fc heterodimer and the use thereof. The heterodimeric protein comprises protein a and protein b, wherein the protein a comprises an IL-15 mutant and a first Fc mutant; the protein b comprises a sushi domain of an IL-15Rα subunit and fragments of other parts of the IL-15Rα subunit, and a second Fc mutant; and the first Fc mutant and the second Fc mutant are selected from a Knob-modified Fc or a Hole-modified Fc, and the modification types of the two are different. It is proven by experiments that the heterodimeric protein provided by the present invention can effectively stimulate the proliferation of NK cells and T cells. In-vivo experiments show that the dimeric protein HL-015-9 inhibits the growth of tumors better than ALT-803 at the same injection dose, and can be used in the preparation of drugs or preparations for treating diseases such as tumors and/or virus infections.
Inventors:
ZHOU HAIPING (CN)
HONG HAIYAN (CN)
ZHANG XUELIANG (CN)
LI CHONGYANG (CN)
TAN XIAOLU (CN)
HONG HAIYAN (CN)
ZHANG XUELIANG (CN)
LI CHONGYANG (CN)
TAN XIAOLU (CN)
Application Number:
PCT/CN2023/110205
Publication Date:
February 22, 2024
Filing Date:
July 31, 2023
Export Citation:
Assignee:
HI LAB BEIJING BIOTECH CO LTD (CN)
International Classes:
C07K19/00; A61K38/20; A61P35/00; A61P37/00; C12N15/62; C12N15/63
Domestic Patent References:
| WO2015103928A1 | 2015-07-16 | |||
| WO2021119429A1 | 2021-06-17 | |||
| WO2020146835A1 | 2020-07-16 | |||
| WO2021054867A1 | 2021-03-25 |
Foreign References:
| CN114341189A | 2022-04-12 | |||
| CN104093841A | 2014-10-08 |
Attorney, Agent or Firm:
JEEKAI & PARTNERS (CN)
Download PDF:
Previous Patent: AI MODEL TRAINING METHOD AND APPARATUS, AND DEVICE AND READABLE STORAGE MEDIUM
Next Patent: TIME-SERVICE METHOD AND APPARATUS
Next Patent: TIME-SERVICE METHOD AND APPARATUS